Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




Workgroup Sets Priorities to Harmonize Standards for EHRs and Research



By Ann Neuer

January 5, 2009 | The much anticipated convergence of data between clinical trials and electronic health records (EHR) is heading toward reality with the recent formation of the EHR Clinical Research Value Case Workgroup. Convened in November by the American National Standards Institute (ANSI), the workgroup is a cross-section of experts from industry, academia, standards organizations, and government who have come together to identify priorities for the harmonization of technical standards needed to ensure the interoperability of EHRs and global clinical research applications.

“It’s a neutral group of stakeholder representatives that will set priorities for interoperability specification development in the clinical research space,” says Rebecca Kush, president and CEO of the Clinical Data Interchange Standards Consortium (CDISC) and co-chair of this initiative.

Kush explains that when the workgroup held its first meeting in November, she and fellow co-chair Gregory Downing, director of the Initiative on Personalized Health Care at the Department of Health and Human Services (HHS), came prepared with five suggested priorities. By the end of that session, however, one key priority, known as the value case, emerged—to identify a core (common) set of data fields that could be exchanged between EHRs and systems that support clinical research. “This refers to a set of data fields found in EHRs that would have application to international research studies, such as demographic data. This information could be collected once in the EHR and could then populate a case report form for a clinical research study,” Kush remarks. With this value case creating a foundation, future priorities are expected to take shape around EHRs for purposes of patient recruitment, adverse event reporting, pharmacovigilance, and pharmacogenomics.

Rebecca_Kush
Rebecca Kush
In order for the information to flow effectively, standards must be identified, and this is where it gets complicated. For some time, the clinical research sector had been anxious to become part of the multiple federal forays into expanding information technology in health care, such as the Healthcare Information Technology Standards Panel (HITSP), which reports to HHS; the American Health Information Community (AHIC), which set priorities for HITSP and terminated in November; and the AHIC Successor, currently in the midst of developing its governance, and whose funding as a public-private partnership is uncertain. Downing, who opened the door for the clinical research presentation to AHIC in July, says that the connecting of research with federal efforts is critical at this time to avoid the development of divergent and disparate standards that will inhibit the compatibility of EHRs with clinical research platforms. “A number of organizations, such as CDISC and Health Level 7 (HL7) have already developed standards, so we should leverage them instead of re-inventing the wheel,” says Downing.

And things are moving forward within the workgroup. The value case is currently being written by a contractor for HHS, with input from the workgroup. An initial draft of the value case is expected in early January, to be followed by a mid-January conference call to seek comments from members of the workgroup. “By early February, we’re hoping to have this finished so it can be sent to HITSP, which will form technical committees to select the standards that support this value case and they will write up the interoperability specifications,” Kush explains.

One of the key issues is the dire need for funding if the work is to continue. There is no federal funding to support this project, and it is unknown if the new administration will fund this work. The workgroup hopes there will be a “glide path” for this work when the AHIC Successor is established. In the interim, ANSI and Kush are looking to stakeholders for financial support. She estimates that $250,000 to $300,000 is needed from public and private-sector sources for ANSI to be able to contract with HITSP for the development of the interoperability specifications. “We cannot go forward in February with the HITSP work without money. In this economy, we need a lot of contributors and people in clinical research, personalized medicine, pharmacogenomics, anyone who would ever want to use EHR data for their studies should contribute,” Kush comments.


This story first appeared in eCliniqua, one of Bio-IT World’s free eNewsletters. Subscribe here.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .